Darzalex Faspro (Daratumumab and hyaluronidase-fihj) for Myeloma

Overview
Darzalex Faspro is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat newly diagnosed, relapsed, and refractory multiple myeloma in adults, often in combination with other medications. Darzalex Faspro is also referred to by its drug name, daratumumab and hyaluronidase-fihj.

Darzalex Faspro is a member of a class of drugs called biologics. Darzalex Faspro is a monoclonal antibody. Darzalex Faspro is believed to work by binding to cancer cells, causing cell death.

How do I take it?
Prescribing information states that Darzalex Faspro is given by subcutaneous injection (injection under your skin) by a healthcare professional. Darzalex Faspro is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Darzalex Faspro is available only as a subcutaneous injection.

Side effects
The FDA-approved label for Darzalex Faspro lists common side effects including respiratory tract infection, constipation, nausea, fatigue, fever, diarrhea, cough, insomnia, vomiting, and back pain.

Rare but serious side effects listed for Darzalex Faspro include severe injection reactions, low blood cell counts, and fetal harm.

For more details about this treatment, visit:

Darzalex Faspro — Janssen
https://www.darzalex.com

What Is Darzalex/Darzalex Faspro? — Multiple Myeloma Research Foundation
https://themmrf.org/multiple-myeloma/treatment-...